<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02790281</url>
  </required_header>
  <id_info>
    <org_study_id>07031-01</org_study_id>
    <nct_id>NCT02790281</nct_id>
  </id_info>
  <brief_title>A Study to Investigate Interleukin-6 (IL-6) and IL-6/Soluble IL-6 Receptor (sIL-6R) Complex Levels in Subjects With Active Inflammatory Bowel Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure IL-6 and IL-6/sIL-6R complex levels in subjects with
      active moderate to severe ulcerative colitis or Crohn's disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Exploratory: Levels of IL-6/sIL-6R Complex</measure>
    <time_frame>At Day 1</time_frame>
    <description>Blood sample was taken for analysis of levels of IL-6/sIL6-R complex.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exploratory: Levels of IL-6</measure>
    <time_frame>At Day 1</time_frame>
    <description>Blood sample was taken for analysis of levels of IL-6.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exploratory: Levels of C-reactive Protein (CRP)</measure>
    <time_frame>At Day 1</time_frame>
    <description>Blood sample was taken for analysis of levels of CRP.</description>
  </primary_outcome>
  <enrollment type="Actual">33</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood sample collected at a single visit</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Men and women seeking medical support due to present, active moderate to severe ulcerative
        colitis or Crohn's disease (newly diagnosed or during disease relapse).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects diagnosed with active moderate to severe ulcerative colitis (*partial Mayo ≥
             5) or Crohn's disease (Harvey &amp; Bradshaw ≥ 8) *partial Mayo: 9-point scale that
             excludes the endoscopic components of the Mayo score

        Exclusion Criteria:

          -  Presence of another inflammatory disease, except for mild cutaneous psoriasis

          -  Concomitant gastrointestinal infection or otherwise serious infection including
             Crohn's disease infectious complication

          -  Treatment with Infliximab, Adalimumab, Certolizumab Pegol or other immune-modulating
             biologics within 8 weeks prior to the visit

          -  Having a known or suspected gastrointestinal or otherwise serious infection within 8
             weeks prior to the visit

          -  Concomitant diagnosed or suspected malignant disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herlev hospital (there may be other sites in this country)</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital (there may be other sites in this country)</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2016</study_first_submitted>
  <study_first_submitted_qc>June 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2016</study_first_posted>
  <results_first_submitted>November 2, 2016</results_first_submitted>
  <results_first_submitted_qc>January 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 6, 2017</results_first_posted>
  <last_update_submitted>January 13, 2017</last_update_submitted>
  <last_update_submitted_qc>January 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from amongst the subjects seeking medical support due to present, active moderate to severe ulcerative colitis or Crohn’s disease (newly diagnosed or during disease relapse) at four sites in two countries (Denmark and Sweden) between 10 Dec 2014 to 20 Aug 2015.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>Subjects included were diagnosed with active moderate to severe ulcerative colitis or Crohn’s disease and C-reactive protein (CRP) &gt;5 mg/L.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set, consisted of all eligible subjects with CRP &gt;5 mg/L.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>Subjects included were diagnosed with active moderate to severe ulcerative colitis or Crohn’s disease and C-reactive protein (CRP) &gt;5 mg/L.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.6" spread="16.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Exploratory: Levels of IL-6/sIL-6R Complex</title>
        <description>Blood sample was taken for analysis of levels of IL-6/sIL6-R complex.</description>
        <time_frame>At Day 1</time_frame>
        <population>All eligible subjects with CRP &gt;5 mg/L.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>Subjects included were diagnosed with active moderate to severe ulcerative colitis or Crohn’s disease and C-reactive protein (CRP) &gt;5 mg/L.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory: Levels of IL-6/sIL-6R Complex</title>
          <description>Blood sample was taken for analysis of levels of IL-6/sIL6-R complex.</description>
          <population>All eligible subjects with CRP &gt;5 mg/L.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Levels of IL-6/sIL6-R complex were below level of detection.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exploratory: Levels of IL-6</title>
        <description>Blood sample was taken for analysis of levels of IL-6.</description>
        <time_frame>At Day 1</time_frame>
        <population>All eligible subjects with CRP &gt;5 mg/L</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>Subjects included were diagnosed with active moderate to severe ulcerative colitis or Crohn’s disease and C-reactive protein (CRP) &gt;5 mg/L.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory: Levels of IL-6</title>
          <description>Blood sample was taken for analysis of levels of IL-6.</description>
          <population>All eligible subjects with CRP &gt;5 mg/L</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Levels of IL-6 were below level of detection.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exploratory: Levels of C-reactive Protein (CRP)</title>
        <description>Blood sample was taken for analysis of levels of CRP.</description>
        <time_frame>At Day 1</time_frame>
        <population>All eligible subjects with CRP &gt;5 mg/L</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>Subjects included were diagnosed with active moderate to severe ulcerative colitis or Crohn’s disease and C-reactive protein (CRP) &gt;5 mg/L.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory: Levels of C-reactive Protein (CRP)</title>
          <description>Blood sample was taken for analysis of levels of CRP.</description>
          <population>All eligible subjects with CRP &gt;5 mg/L</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Levels of CRP were below level of detection.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>No data for adverse event was collected in this study as no investigational medicinal product was administered to the subjects.</time_frame>
      <desc>Serious and Other (Not Including Serious) Adverse Events were not monitored/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Overall Study</title>
          <description>Subjects included were diagnosed with active moderate to severe ulcerative colitis or Crohn’s disease and C-reactive protein (CRP) &gt;5 mg/L.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Manuscripts or abstracts will be prepared in collaboration between Ferring and the Investigators.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Development Support</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

